InMed shares surge 29.27% premarket after completing key pharmacokinetic studies for Alzheimer's candidate INM-901, advancing to human trials.

InMed Pharmaceuticals Inc. surged 29.27% in premarket trading following the announcement of successful pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models. The data demonstrated favorable bioavailability, no adverse neural or behavioral effects, and support for advancing to first human trials, alongside preparations for a pre-IND meeting with the FDA. This milestone, coupled with positive in vivo therapeutic exposure results, reinforced investor confidence in the drug’s development potential. The news aligned with prior disclosures in after-hours trading, where shares had risen 21.98% on similar updates, though the premarket rally reflected renewed momentum ahead of further regulatory and clinical steps.